Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stage III unresectable NSCLC biomarker platform study
NL-OMON53740Terminated
- Sponsor
- Roche
- Start
- Dec 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised trial of alectinib, entrectinib, pralsetinib and durvalumab in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Started Dec 2022; status: terminated.
02
Drugs
alectinibentrectinibpralsetinibdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON53740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53740.